An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Seres Therapeutics to Present at Canaccord Genuity 42nd Annual Growth Conference
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Seres Therapeutics, Inc. (Nasdaq: MCRB), a leader in microbiome therapeutics, announced that CEO Eric Shaff will participate in the Canaccord Genuity 42nd Annual Growth Conference on August 10 at 12:30 p.m. ET. An audio webcast of the event will be accessible on the company's website, with a replay available for 21 days.
Seres is known for its SER-109 program, the first microbiome drug candidate to achieve positive pivotal clinical results, aimed at preventing C. difficile infection recurrences, and is also developing SER-155 to reduce infections in transplant patients.
Positive
None.
Negative
None.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--
Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that Eric Shaff, President and Chief Executive Officer, will participate in a discussion at the Canaccord Genuity 42nd Annual Growth Conference on Wednesday, August 10 at 12:30 p.m. ET.
An audio webcast of the presentation will be available under the “Investors and News” section of Seres’ website. A replay of the presentation will become available approximately one hour after the event and will be archived for approximately 21 days.
About Seres Therapeutics
Seres Therapeutics, Inc. (Nasdaq: MCRB) is a leading microbiome therapeutics company developing a novel class of multifunctional bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. Seres’ SER-109 program achieved the first-ever positive pivotal clinical results for a targeted microbiome drug candidate and has obtained Breakthrough Therapy and Orphan Drug designations from the FDA. The SER-109 program is being advanced to prevent further recurrences of C. difficile infection and has potential to become a first-in-class FDA-approved microbiome therapeutic. Seres is evaluating SER-155 in a Phase 1b study in patients receiving allogeneic hematopoietic stem cell transplantation to reduce incidences of gastrointestinal infections, bloodstream infections and graft-versus-host disease as well as additional preclinical stage programs targeting Infection Protection in medically compromised patients. The Company is also conducting research to inform further development of microbiome therapeutics for ulcerative colitis.
When will Seres Therapeutics participate in the Canaccord Genuity 42nd Annual Growth Conference?
Seres Therapeutics will participate on August 10 at 12:30 p.m. ET.
How can I listen to the Seres Therapeutics conference presentation?
An audio webcast of the presentation will be available on the Seres Therapeutics website under the 'Investors and News' section.
What is the SER-109 program by Seres Therapeutics?
SER-109 is a microbiome drug candidate designed to prevent recurrences of C. difficile infection and has received Breakthrough Therapy and Orphan Drug designations from the FDA.
What other programs is Seres Therapeutics developing?
Seres is developing SER-155 in a Phase 1b study to reduce gastrointestinal infections and is researching microbiome therapeutics for ulcerative colitis.
